Loading
A phase 2 trial of Capecitabine, Cisplatin and Streptozocin in Pancreatic neuroendocrine tumours, run by Cambridge University Hospitals NHS Foundation Trust, completed.
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors is a phase 2 interventional study registered as NCT00602082 by Cambridge University Hospitals NHS Foundation Trust, with 84 participants recorded, started 2005-08 and reaching its primary completion in 2009-12. Interventions recorded: capecitabine, cisplatin, streptozocin, DNA analysis, RNA analysis, protein analysis, proteomic profiling, laboratory biomarker analysis. Conditions recorded: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor.
Linked to the drug Streptozocin because the registry names it among its interventions and Pancreatic neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Streptozocin and the tag pipeline.
Shares Capecitabine, Cisplatin and the tag pipeline.
Shares Pancreatic neuroendocrine tumours and the tag pipeline.
Shares Capecitabine, Cisplatin and the tag pipeline.
Shares Capecitabine, Cisplatin and the tag pipeline.
Shares Pancreatic neuroendocrine tumours and the tag pipeline.
Shares Capecitabine and the tag pipeline.
Shares Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/